Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy

@article{Li2019ActivatingCP,
  title={Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy},
  author={Anping Li and Ming Yi and Shuang Qin and Yongping Song and Q. Chu and Kongming Wu},
  journal={Journal of Hematology \& Oncology},
  year={2019},
  volume={12}
}
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor mass. Cancer immunotherapy eradicates tumor cells by enhancing multiple steps in cancer-immunity cycle including antigen presentation, T cell priming, activation, and immune killing activity. Immunotherapy has been verified as an effective strategy in multiple cancers, but some problems still exist in actual clinical practice such as frequent primary and adaptive… Expand
View on Springer
jhoonline.biomedcentral.com
58 Citations
Highly Influential Citations
1
Background Citations
22
Methods Citations
1

58 Citations

Citation Type

Citation Type

cGAS-STING, an important pathway in cancer immunotherapy
Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy
Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway
cGAS-STING signaling in cancer immunity and immunotherapy.
Prospects for combining immune checkpoint blockade with PARP inhibition
Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity.
Cancer immunotherapy with γδ T cells: many paths ahead of us
STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application
Radiotherapy-Mediated Immunomodulation and Anti-Tumor Abscopal Effect Combining Immune Checkpoint Blockade
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 118 REFERENCES
The host STING pathway at the interface of cancer and immunity.
Cancer immunotherapy beyond immune checkpoint inhibitors
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.
A STING-Activating Nanovaccine for Cancer Immunotherapy
Established T Cell–Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade
Oncology meets immunology: the cancer-immunity cycle.
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
...
1
2
3
4
5
...